Geldanamycin and 17-Allylamino-17-demethoxygeldanamycin Potentiate the in Vitro and in Vivo Radiation Response of Cervical Tumor Cells via the Heat Shock Protein 90-Mediated Intracellular Signaling and Cytotoxicity

Cancer Research

Volumn 63, Issue 24, 2003, Pages 8984-8995

  Bisht, Kheem S ^a   Bradbury, C Matthew ^a   Mattson, David ^a   Kaushal, Aradhana ^a   Sowers, Anastasia ^a   Markovina, Stephanie ^a   Ortiz, Karen L ^a   Sieck, Leah K ^a   Isaacs, Jennifer S ^a   Brechbiel, Martin W ^a   Mitchell, James B ^a   Neckers, Leonard M ^a   Gius, David ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

17 ALLYLAMINO 17 DEMETHOXYGELDANAMYCIN; 17-(ALLYLAMINO)-17-DEMETHOXYGELDANAMYCIN; AKT1 PROTEIN; ANSAMYCIN DERIVATIVE; ANTINEOPLASTIC AGENT; ANTINEOPLASTIC ANTIBIOTIC; CYCLIC AMP DEPENDENT PROTEIN KINASE; DRUG DERIVATIVE; EPIDERMAL GROWTH FACTOR RECEPTOR 2; GELDANAMYCIN; GLUCOSE TRANSPORTER 1; HEAT SHOCK PROTEIN 90; MITOGEN ACTIVATED PROTEIN KINASE 1; MOLECULAR MARKER; PROTEIN KINASE B; PROTEIN KINASE LYN; QUINONE DERIVATIVE; RADIOSENSITIZING AGENT; RAF PROTEIN; RIFABUTIN; UNCLASSIFIED DRUG; VASCULOTROPIN;

ANIMAL; ANIMAL EXPERIMENT; ANIMAL MODEL; APOPTOSIS; ARTICLE; CELL CYCLE; CELL IMMORTALIZATION; CELL PROLIFERATION; CELL SURVIVAL; CONTROLLED STUDY; DOSE RESPONSE; DOWN REGULATION; DRUG CYTOTOXICITY; DRUG EFFECT; DRUG EXPOSURE; DRUG POTENTIATION; DRUG SCREENING; DRUG TARGETING; FEMALE; GENE EXPRESSION REGULATION; HELA CELL; HUMAN; HUMAN CELL; IONIZING RADIATION; MOUSE; MOUSE STRAIN; MULTIMODALITY CANCER THERAPY; NONHUMAN; NUDE MOUSE; PHYSIOLOGY; PRIORITY JOURNAL; PROTEIN DEGRADATION; RADIATION RESPONSE; RADIOSENSITIZATION; SIGNAL TRANSDUCTION; UTERINE CERVIX CANCER; UTERINE CERVIX TUMOR; WART VIRUS;

ANIMALS; ANTIBIOTICS, ANTINEOPLASTIC; BENZOQUINONES; COMBINED MODALITY THERAPY; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG SYNERGISM; FEMALE; HELA CELLS; HSP90 HEAT-SHOCK PROTEINS; HUMANS; LACTAMS, MACROCYCLIC; MICE; MICE, INBRED C3H; MICE, NUDE; QUINONES; RADIATION-SENSITIZING AGENTS; RIFABUTIN; SIGNAL TRANSDUCTION; UTERINE CERVICAL NEOPLASMS; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 9144261127     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (61)

1. Lindquist, S. The heat-shock response. Annu. Rev. Biochem., 55: 1151-1191, 1986.
2. Morimoto, R. I., Kline, M. P., Bimston, D. N., and Cotto, J. J. The heat-shock response: regulation and function of heat-shock proteins and molecular chaperones. Essays Biochem., 32: 17-29, 1997.
3. Neckers, L., Schulte, T. W., and Mimnaugh, E. Geldanamycin as a potential anticancer agent: its molecular target and biochemical activity. Investig. New Drugs, 17: 361-373, 1999.
4. Neckers, L. HSP90 inhibitors as novel cancer chemotherapeutic agents. Trends Mol. Med., 8: 55-61, 2002.
5. Ferrarini, M., Heltai, S., Zocchi, M. R., and Rugarli, C. Unusual expression and localization of heat-shock proteins in human tumor cells. Int. J. Cancer, 51: 613-619, 1992.
6. Whitesell, L., Shifrin, S. D., Schwab, G., and Neckers, L. M. Benzoquinonoid ansamycins possess selective tumoricidal activity unrelated to src kinase inhibition. Cancer Res., 52: 1721-1728, 1992.
7. Schnur, R. C., Corman, M. L., Gallaschun, R. J., Cooper, B. A., Dee, M. F., Doty, J. L., Muzzi, M. L., Moyer, J. D., DiOrio, C. I., Barbacci, E. G., Miller, P. E., Pollalk, V. A., Savage, D. M., Sloan, D. E., Pustilnik, L. R., and Moyer, M. P. erbB-2 oncogene inhibition by geldanamycin derivatives: synthesis, mechanism of action, and structure-activity relationships. J. Med. Chem., 38: 3806-3812, 1995.
8. Grenert, J. P., Sullivan, W. P., Fadden, P., Haystead, T. A., Clark, J., Mimnaugh, E., Krutzsch, H., Ochel, H. J., Schulte, T. W., Sausville, E., Neckers, L. M., and Toft, D. O. The amino-terminal domain of heat shock protein 90 (hsp90) that binds geldanamycin is an ATP/ADP switch domain that regulates hsp90 conformation. J. Biol. Chem., 272: 23843-23850, 1997.
9. Prodromou, C., Roe, S. M., O'Brien, R., Ladbury, J. E., Piper, P. W., and Pearl, L. H. Identification and structural characterization of the ATP/ADP-binding site in the Hsp90 molecular chaperone. Cell, 90: 65-75, 1997.
10. Stebbins, C. E., Russo, A. A., Schneider, C., Rosen, N., Hartl, F. U., and Pavletich, N. P. Crystal structure of an Hsp90-geldanamycin complex: targeting of a protein chaperone by an antitumor agent. Cell, 89: 239-250, 1997.
11. An, W. G., Schnur, R. C., Neckers, L., and Blagosklonny, M. V. Depletion of p185erbB2, Raf-1, and mutant p53 proteins by geldanamycin derivatives correlates with antiproliferative activity. Cancer Chemother. Pharmacol., 40: 60-64, 1997.
12. Obermann, W. M., Sondermann, H., Russo, A. A., Pavletich, N. P., and Hartl, F. U. In vivo function of HSP90 is dependent on ATP binding and ATP hydrolysis. J. Cell Biol., 143: 901-910, 1998.
13. Workman, P., and Maloney, A. HSP90 as a new therapeutic target for cancer therapy: the story unfolds. Expert Opin. Biol. Ther., 2: 3-24, 2002.
14. Munster, P. N., Srethapakdi, M., Moasser, M. M., and Rosen, N. Inhibition of heat shock protein 90 function by ansamycins causes the morphological and functional differentiation of breast cancer cells. Cancer Res., 61: 2945-2952, 2001.
15. Chiosis, G., Huezo, H., Rosen, N., Mimnaugh, E., Whitesell, L., and Neckers, L. 17AAG: low target binding affinity and potent cell activity: finding an explanation. Mol. Cancer Ther., 2: 123-129, 2003.
16. Munster, P. N., Marchion, D. C., Basso, A. D., and Rosen, N. Degradation of HER2 by ansamycins induces growth arrest and apoptosis in cells with HER2 overexpression via a HER3, phosphatidylinositol 3′-kinase-AKT-dependent pathway. Cancer Res., 62: 3132-3137, 2002.
17. Schulte, T. W., and Neckers, L. M. The benzoquinone ansamycin 17-allylamino-17-demethoxygeldanamycin binds to HSP90 and shares important biologic activities with geldanamycin. Cancer Chemother. Pharmacol., 42: 273-279, 1998.
18. Mimnaugh, E. G., Chavany, C., and Neckers, L. Polyubiquitination and proteasomal degradation of the p185c-erbB-2 receptor protein-tyrosine kinase induced by geldanamycin. J. Biol. Chem., 271: 22796-22801, 1996.
19. Doong, H., Rizzom, K., Fangm, S., Kulpam, V., Weissmanm, A. M., and Kohn, E. C. CAIR-1/BAG-3 abrogates heat shock protein-70 chaperone complex-mediated protein degradation: accumulation of poly-ubiquitinated Hsp90 client proteins. J. Biol. Chem., 278: 28490-28500, 2003.
20. Park, J. W., Yeh, M. W., Wong, M. G., Lobo, M., Hyun, W. C., Duh, Q. Y., and Clark, O. H. The heat shock protein 90-binding geldanamycin inhibits cancer cell proliferation, down-regulates oncoproteins, and inhibits epidermal growth factor-induced invasion in thyroid cancer cell lines. J. Clin. Endocrinol. Metab., 88: 3346-3353, 2003.
21. Solit, D. B., Basso, A. D., Olshen, A. B., Scher, H. I., and Rosen, N. Inhibition of heat shock protein 90 function down-regulates Aktl kinase and sensitizes tumors to Taxol. Cancer Res., 63: 2139-2144, 2003.
22. Blagosklonny, M. V., Toretsky, J., and Neckers, L. Geldanamycin selectively destabilizes and conformationally alters mutated p53. Oncogene, 11: 933-939, 1995.
23. Dasgupta, G., and Momand, J. Geldanamycin prevents nuclear translocation of mutant p53. Exp. Cell Res., 237: 29-37, 1997.
24. Weichselbaum, R. R., Hallahan, D. E., Fuks Z., and Kufe, D. Radiation induction of immediate early genes: effectors of the radiation-stress response. Int. J. Radiat. Oncol. Biol. Phys., 30: 229-234, 1994.
25. Maity, A., Kao, G. D., Muschel, R. J., and McKenna, W. G., Potential molecular targets for manipulating the radiation response. Int. J. Radiat. Oncol. Biol. Phys., 37: 639-653, 1997.
26. Wei, J., Botero, A., Hirota, K., Bradbury, C. M., Markovina, S., Laszlo, A., Spitz, D. R., Goswami, P. C., Yodoi, J., and Gius, D. Thioredoxin nuclear translocation and interaction with redox factor-1 activate the AP-1 transcription factor in response to ionizing radiation. Cancer Res., 60: 6688-6695, 2000.
27. Karimpour, S., Lou, J., Lin, L. L., Rene, L. M., Lagunas, L., Ma, X., Karra, S., Bradbury, C. M., Markovina, S., Goswami, P. C., Spitz, D. R., Hirota, K., Kalvakolanu, D. V., Yodoi, J., and Gius, D. Thioredoxin reductase regulates AP-1 activity as well as thioredoxin nuclear localization via active cysteines in response to ionizing radiation. Oncogene, 12: 6317-6327, 2002.
28. Dewey, W. C., Freeman, M. L., and Raaphorst, G. P. Cell biology of hyperthermia and radiation. In: R. E. Meyn, and H. R. Withers (eds.), Radiation Biology in Cancer Research, pp. 589-613. New York, Raven Press, Ltd., 1980.
29. Locke, J. E., Bradbury, C. M., Wei, J., Shah, S., Renee, L. M., Clemens, R. A., Roti Roti, J. L., Horikoshi, N., and Gius, D. Indomethacin lowers the threshold thermal exposure for hyperthermic radiosensitization and heat shock inhibition of ionizing radiation-induced NF-κB. Int. J. Radiat. Biol., 78: 493-502, 2002.
30. 2, and cisplatin are inhibited by indomethacin in oxidative stress resistant cells. Cancer Res., 61: 3486-3492, 2001.
31. Connor, W. G., Gerner, E. W., Miller, R. C., and Boone, M. L. Prospects for hyperthermia in human cancer therapy. Part II: implications of biological and physical data for applications of hyperthermia to man. Radiology, 123: 497-503, 1977.
32. Diamond, D. A., Parsian, A., Hunt, C. R., Lofgren, S., Spitz, D. R., Goswami, P., and Gius, D. Redox factor-1 (Ref-1) mediates the activation of AP-1 in HeLa and NIH 3T3 cells in response to heat. J. Biol. Chem., 274: 16959-16964, 1999.
33. Curry, H. A., Clemens, R. A., Shah, S., Bradbury, C. M., Botero, A., Goswami, P., and Gius, D. Heat shock inhibits radiation-induced nuclear localization and activation of NF-κB DNA-binding. Possible role in radiation sensitization of tumor cells. J. Biol. Chem., 274: 23061-23067, 1999.
34. Morimoto, R. I. Regulation of the heat shock transcriptional response: cross-talk between a family of heat shock factors, molecular chaperones, and negative regulators. Genes Dev., 12: 3788-3796, 1998.
35. Ahn, S. G., and Thiele, D. J. Redox regulation of mammalian heat shock factor 1 is essential for Hsp gene activation and protection from stress. EMBO J., 17: 516-528, 2003.
36. Polla, B. S., Kentengwa, S., Francois, D., Salvioloi, S., Franceschi, C., Marsac, C., and Cossarizza, A. Mitochondria are selective targets for the protective effects of heat shock against oxidative injury. Proc. Natl. Acad. Sci. USA, 93: 6458-6463, 1996.
37. Cotto, J., Kline, M., and Morimoto, R. Activation of heat shock factor 1 DNA binding precedes stress-induced serine phosphorylation. Evidence for a multistep pathway of regulation. J. Biol. Chem., 271: 3355-3358, 1996.
38. Jurivich, D. A., Sistonen, L., Sarge, K. D., and Morimoto, R. I. Effect of sodium salicylate on the human heat shock response. Science (Wash. DC), 265: 1243-1245. 1992.
39. Jurivich, D. A., Pachetti, C., Qiu, L., and Welk, J. F. Salicylate triggers heat shock factor differently than heat. J. Biol. Chem., 270: 24489-24495, 1995.
40. Yamamoto, Y., Yin, M. J., Lin, K. M., and Gaynor, R. B. Sulindac inhibits activation of the NF-κB pathway. J. Biol. Chem., 274: 27307-27314, 1999.
41. Bradbury, C. M., Markovina, S., Wei, J., Renee, L. M., Zoberi, I., Horikoshi, N., and Gius, D. The role of NF-κB as one downstream target of p38 MAPK in the process of indomethacin-induced radiosensitization. Cancer Res., 61: 7689-7696, 2001.
42. Palayoor, S. T., Bump, E. A., Calderwood, S. K., Bartol, S., and Coleman, C. N. Combined antitumor effect of radiation and ibuprofen in human prostate carcinoma cells. Clin. Cancer Res., 4: 763-771, 1998.
43. Pelech, S., Sutter, C., and Zhang, H. Protein kinase multiblot analysis. In: D. Terrian (ed.), Methods in Molecular Medicine Series: Cancer Cell Signaling Kinetworks, Vol. 218, pp. 99-111. Totowa, NJ: Humana Press, 2003.
44. Dignam, J. D. Preparation of extracts from higher eukaryotes. Methods Enzymol., 182: 194-203, 1990.
45. Dent, P., Yacoub, A., Contessa, J., Caron, R., Amorino, G., Valerie, K., Hagan, M. P., Grant, S., and Schmidt-Ullrich, R. Stress and radiation-induced activation of multiple intracellular signaling pathways. Radiat. Res., 159: 283-300, 2003.
46. Sartor, C. I. Epidermal growth factor family receptors and inhibitors: radiation response modulators. Semin. Radiat. Oncol., 13: 22-30, 2003.
47. Isaacs, J. S., Jung, Y. J., Mimnaugh, E. G., Martinez, A., Cutfitta, F., and Neckers, L. M. Hsp90 regulates a von Hippel Lindau-independent hypoxia-inducible factor-1 α-degradative pathway. J. Biol. Chem., 277: 29936-29944, 2002.
48. Stubenrauch, F., and Laimins, L. A. Human papillomavirus life cycle: active and latent phases. Semin. Cancer Biol., 9: 379-386, 1999.
49. Munger, K., and Howley, P. M. Human papillomavirus immortalization and transformation functions. Virus Res., 89: 213-228, 2002.
50. Song, S., Liem, A., Miller, J. A., and Lambert, P. F. Human papillomavirus types 16 E6 and E7 contribute differently to carcinogenesis. Virology, 267: 141-150, 2000.
51. Helt, A. M., and Galloway, D. A. Destabilization of the retinoblastoma tumor suppressor by human papillomavirus type 16 E7 is not sufficient to overcome cell cycle arrest in human keratinocytes. J. Virol., 75: 6737-6747, 2001.
52. 2 checkpoint function and chromosomal destabilization are linked in human fibroblasts expressing human papillomavirus type 16 E6. Cell Growth Differ., 8: 1105-1114, 1997.
53. Bedell, M. A., Jones, K. H., Grossman, S. R., and Laimins, L. A. Identification of human papillomavirus type 18 transforming genes in immortalized and primary cells. J. Virol., 63: 1247-1255, 1989.
54. Demers, G. W., Foster, S. A., Halbert, C. L., and Galloway, D. A. Growth arrest by induction of p53 in DNA damaged keratinocytes is bypassed by human papillomavirus 16 E7. Proc. Natl. Acad. Sci. USA, 91: 4382-4386, 1994.
55. Demers, G. W., Halbert, C. L., and Galloway, D. A. Elevated wild-type p53 protein levels in human epithelial cell lines immortalized by the human papillomavirus type 16 E7 gene. Virology, 198: 169-174, 1994.
56. Tsuruo, T., Naito, M., Tomida, A., Fujita, N., Mashima, T., Sakamoto, H., and Haga, N. Molecular targeting therapy of cancer: drug resistance, apoptosis and survival signal. Cancer Sci., 94: 15-21, 2003.
57. Drevs, J., Medinger, M., Schmidt-Gersbach, C., Weber, R., and Unger, C. Receptor tyrosine kinases: the main targets for new anticancer therapy. Curr. Drug Targets, 4: 113-121, 2003.
58. Laird, A. D., and Cherrington, J. M. Small molecule tyrosine kinase inhibitors: clinical development of anticancer agents. Expert Opin. Investig. Drugs, 12: 51-64, 2003.
59. Gius, D., Botero, A., Shah, S., and Curry, H. A. Intracellular oxidation/reduction status in the regulation of transcription factors AP-1 and NF-κB. Toxicol. Lett., 106: 93-106, 1999.
60. Roti Roti, J. L., Gius, D., VanderWaal, R. P., and Xu, M. Changes in sub-nuclear structures and functional perturbations: implications for radiotherapy. J. Cell. Biochem., 35: 142-150, 2000.
61. Kamal, A., Thao, L., Sensintaffar, J., Zhang, L., Boehm, M. F., Fritz, L. C., and Burrows, F. J. A high-affinity conformation of Hsp90 confers tumour selectivity on Hsp90 inhibitors. Nature (Lond.), 425: 407-410, 2003.